Vancomycin resistant Enterococci (VRE) - Importance, prevention and management in pediatrics - A review;Vancomycin-resistente Enterokokken (VRE) - Übersicht zu bedeutung, prävention und management in der pädiatrie

Hygiene + Medizin

Volumn 29, Issue 7-8, 2004, Pages 259-275

  Simon, A ^a   Groger N ^a   Engelhart, S ^a   Molitor, G ^a   Exner, M ^a   Bode, U ^a   Fleischhack, G ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Infection control; Pediatric patients; Vancomycin resistant enterococci

Indexed keywords

ANTIBIOTIC AGENT; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CYCLOSPORIN; DALFOPRISTIN PLUS QUINUPRISTIN; FOSFOMYCIN; GENTAMICIN; GLYCOPEPTIDE; IMMUNOSUPPRESSIVE AGENT; LINEZOLID; METRONIDAZOLE; MYCOPHENOLIC ACID; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; RAMOPLANIN; STREPTOMYCIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL COLONIZATION; BACTERIAL COUNT; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; CENTRAL VENOUS CATHETER; CHILD; CLINICAL TRIAL; COOPERATION; DRUG CHOICE; DRUG EXPOSURE; DRUG INDICATION; DRUG USE; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; FECES ANALYSIS; GENE EXPRESSION; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INTENSIVE CARE; LIVESTOCK; MEAT INDUSTRY; NEONATOLOGY; NONHUMAN; ONCOLOGY; PEDIATRICS; REVIEW; RISK FACTOR; TREATMENT INDICATION; URINARY TRACT INFECTION; URINE CATHETER; VANA GENE; VANB GENE;

EID: 4544368864     PISSN: 01723790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (189)

1. Anonymus Monitoring Hospital-Acquired Infections to Promote Patient Safety - United States, 1990-1999. MMWR 2000; 49: 149-153.
2. Babcock HM, Ritchie DJ, Christiansen E, Starlin R, Little R, Stanley S: Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis 2001; 32: 1373-1375.
3. Bates J, Jordens Z, Selkon JB: Evidence of an Animal Origin of Vancomycin-Resistant Enterococci. Lancet 1993; 342: 490-491.
4. Beezhold D, Slaughter S, Hayden MK, Matushek M, Nathan C, Trenholme GM: Skin Colonization with Vancomycin-Resistant Enterococci Among Hospitalized Patients with Bacteriemia. Clin Infect Dis 1997; 24: 704-706.
5. Hingen E, Lambert-Zechovsky N, Mariani-Kurkdjian P, Cezard JP, Navarre J: Bacteriemia Caused by a Vancomycin-Resistant Enterococcus. [Letter] Pediatr Infect Dis J 1989; 8: 475-476.
6. Bingen EH, Denamur E, Lambert-Zechovsky NY, Elion J: Evidence for the Genetic Unrelatedness of Nosocomial Vancomycin-Resistant Enterococcus faecium Strains in a Pediatric Hospital. J Clin Microbiol 1991; 29: 1888-1892.
7. Bonten MJ, Hayden MK, Nathan C, van Voorhis J, Matushek M, Slaughter S, Rice T, Weinstein RA: Epidemiology of colonisation of patients and environment with vancomycin-resistant enterococci. Lancet 1996; 348: 1615-1619.
8. Boyce JM, Opal SM, Chow JW, Zervos MJ, Potter-Bynoe G, Sherman CB, Romulo RL, Forma S, Medeiros AA: Outbreak of Multidrug-Resistant Enterococcus faecium With Transferable VanB Class Vancomycin Resistance. J Clin Microbiol 1994; 32: 1148-1153.
9. Boyce JM, Pittet D. Healthcare Infection Control Practices Advisory Committee. Society for Healthcare Epidemiology of America. Association for Professionals in Infection Control. Infectious Diseases Society of America. Hand Hygiene Task Force: Guideline for Hand Hygiene in Health-Care Settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infect Control Hosp Epidemiol 2002; 23 [Suppl]: S3-40.
10. Bradley SJ, Wilson AL, Alien MC, Sher HA, Goldstone AH, Scott GM: The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. J Antimicrob Chemother 1999; 43: 261-266.
11. Bratcher DF: Vancomycin-Resistant Enterococci in The Pediatric Patient. Pediatric Infect Dis J 2000; 20: 621-622.
12. Braveny I, Maschmeyer G: Infektionskrankheiten: Diagnostik, Klinik, Therapie. medco Verlag GmbH München 2002.
13. Breathnach A.S. Jenkins D.R., Pedler S.J.: Stethoscopes as Possible Vectors of Infection by Staphylococci. Brit Med J 1992; 305: 1573-1574.
14. Brisse S, Fussing V, Ridwan B, Verhoef J, Willems RJ: Automated ribotyping of vancomycin-resistant Enterococcus faecium isolates. Clin Microbiol 2002; 40: 1977-1984.
15. Brooks S, Khan A, Stoica D, Griffith J, Freideman L, Mukherji R, Hameed R, Schupf N: Reduction in Vancomycin-Resistant Enterococcus and Clostridium difficile Infections Following Change to Tympanic Thermometers. Infect Control Hosp Epidemiol 1998; 19: 333-336.
16. Bures S, Fishbain JT, Uyehara CFT, Parker JM, Berg BW: Computer Keyboards and Faucet Handles as Reservoirs of Nosocomial Pathogens in the Intensive Care Unit. Am J Infect Control 2000; 28: 465-170.
17. Byers KE, Durbin LJ, Simonton BM, Anglim AM, Adel KA, Farr BM: Disinfection of Hospital Rooms Contaminated with Vancomycin-Resistant Enterococcus faecium. Infect Control Hosp Epidemiol 1998; 19: 261-264.
18. Byers KE, Anglim AM, Anneski CJ, Germanson TP, Gold HS, Durbin LJ, Simonton BM, Farr BM.: A hospital epidemic of vancomycin-resistant Enterococcus: risk factors and control. Infect Control Hosp Epidemiol 2001; 22: 140-147.
19. Byers KE, Anglim AM, Anneski CJ, Farr BM: Duration of colonization with vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol 2002; 23: 207-211.
20. Carmeli Y, Eliopoulos GM, Samore MH: Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg Infect Dis 2002; 8: 802-807.
21. Carmeli Y, Eliopoulos G, Mozaffari E, Samore M: Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002; 162: 2223-2238.
22. Carretto E, Barbarini D, Locatelli F, Girali E, Pellegrini N, Perversi L, Grossi P, Marone P, Sonetti F: Vancomycin-Resistant Enterococcus faecium Infection in Three Children Given Allogenic Hematopoetic Stem Cell Transplantation: Clinical and Microbiological Features. Haematologica 2000; 85: 1158-1164.
23. Carver PL, Whang E, VandenBussche HL, Kauffman CA, Malani PN: Risk factors for arthralgias or myalgias associated with quinupristin-dalfopristin therapy. Pharmacotherapy 2003; 23: 159-164.
24. Centers for Disease Control and Prevention: Guidelines for Preventing Opportunistic Infections Among Hematopoetic Stem Cell Transplant Recipients. Recommendations of the Centers for Disease Control and Prevention, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR 2000; 49 [R 10]: 1-125.
25. Centers for Disease Control and Prevention (CDC): Vancomycin-resistant Staphylococcus aureus - New York, 2004. MMWR 2004; 53(15): 322-323.
26. Cetinkaya Y, Falk P, Mayhall CG: Vancomycin-resistant enterococci. Clin Microbiol Rev 2000; 13: 686-707.
27. Christie C, Hammond J, Reising S, Evans-Patterson J: Clinical and Molecular Epidemiology of Enterococcal Bacteriemia in a Pediatric Teaching. Hospital J Pediatr 1994; 125: 392-394.
28. Creti R, Imperi M, Bertuccini L, Fabretti F, Orefici G, Di Rosa R, Baldassarri L: Survey for virulence determinants among Enterococcus faecalis isolated from different sources. J Med Microbiol 2004; 53: 13-20.
29. Dancer SJ: The problem with cephalosporins. Antimicrob Chemother 2001; 48: 463-478.
30. Das Ira, Fraise A, Wise R: Are Glycopeptide-Resistent Enterococci in Animals a Threat to Human Beeings? Lancet 1997; 349:997-998.
31. Datz C, Jungwirth A, Dusch H, Galbvan G, Weiger T: What's on Doctor's Ball Point Pens? Lancet 1997; 350: 1824.
32. de Lencastre H, Brown AE, Chung M, Armstrong D, Tomasz A: Role of transposon Tn5482 in the epidemiology of vancomycin-resistant Enterococcus faecium in the pediatric oncology unit of a New York City Hospital. Microb Drug Resist 1999; 5: 113-129.
33. De Lisle S, Pearl TM: Vancomycin-Resistant Enterococci: A Road Map on how to Prevent the Emergence and Transmission of Antimicrobial Resistance. Chest 2003; 123: 504S-518S.
34. Deutsche Gesellschaft für Hygiene und Mikrobiologie (DGHM): Liste der nach den Richtlinien für die Prüfung chemischer Desinfektionsmittel geprüften und von der Deutschen Gesellschaft für Hygiene und Mikrobiologie als wirksam befundenen Desinfektionsverfahren (inkl. Verfahren zur Händedekontamination und hygienischen Händewaschung). Wiesbaden, mhp-Verlag, Stand Dezember 2003.
35. Donskey CJ, Hoyen CK, Das SM, Helfand MS, Hecker MT: Recurrence of vancomycin-resistant Enterococcus stool colonization during antibiotic therapy. Infect Control Hosp Epidemiol 2002; 23: 436-440.
36. Elsner HA, Sobottka I, Feucht HH, Harps E, Haun C, Mack D, Ganschow R, Laufs R, Kaulfers PM: Nosocomial Outbreak of Vancomycin-Resistant Enterococcus faecium at a German University Pediatric Hospital. Int J Hyg Environ Health 2000; 203: 147-152.
37. Falk PS, Winnike J, Woodmansee C, Desai M, Mayhall G: Outbreak of Vancomycin-Resistant Enterococci in a Burn Unit. Infect Control Hosp Epidemiol 2000; 21: 575-582.
38. Fisher MC: Control of Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus in Hospitalized Children. Pediatr Infect Dis J 1998; 17: 825-826.
39. French G, Rayner D, Branson M, Walsh M: Contamination of Doctors' and Nurses' Pens with Nosocomial Pathogens. Lancet 1998; 351: 213.
40. Fridkin SK, Pear SM, Williamson TH, Galgiani JN, Jarvis WR: The role of understaffing in central venous catheter associated bloodstream infections. Infect Control Hosp Epidemiol 1996; 17: 150-158.
41. Garner JS and the Hospital Infection Control Practices Advisory Committee: Guideline for Isolation Precautions in Hospitals. Infect Control Hosp Epidemiol 1996; 17: 53-80 [http://www.cdc.gov].
42. Geiss HK: Wirkungsweise und mikrobiologisches Spektrum von Quinupristin-Dalfopristin. Chemotherapie Journal 2000; 9 [Suppl. 19]: 18-23.
43. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Suva J Jr: Clostridium difficile - Associated Diarrhea and Colitis. Infect Control Hosp Epidemiol 1995; 16: 459-477.
44. Gerding DN: Is there a Relationship Between Vancomycin-Resistant Enterococcal Infection and Clostridium difficile infection? Clin Infect Dis 1997; 25 [Suppl 2]:S206-S210.
45. Gerding DN: Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an anti-microbial resistance problem. Clin Infect Dis 2004; 38: 646-648.
46. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP: Infections Due to Vancomycin-Resistant Enterococcus faecium Resistant to Linezolid. Lancet 2001; 357: 1179.
47. Gould IM: A Review of the Role of Antibiotic Policies in the Control of Antibiotic Resistance. JAC 1999; 43: 459-465.
48. Gray JW, George RH: Experience of vancomycin-resistant enterococci in a children's hospital. J Hosp Infect 2000; 45: 11-18.
49. Gray JW, Darbyshire PJ, Beath SV, Kelly D, Mann JR: Experience with Quinupristin/Dalfopristin in Treating Infections with Vancomycin-Resistant Enterococcus faecium in children. Pediatr Infect Dis J 2000; 19: 234-238.
50. Green M, Barbadora K, Michaels M: Recovery of Vancomycin-Resistant Enterococci from Pediatric Liver Transplant Recipients. J Clin Microbiol 1991; 29: 2503-2506.
51. Green M: Vancomycin Resistant Enterococci: Impact and Management in Pediatrics. Adv Pediatr Infect Dis 1997; 13: 257-277.
52. Hamel JC, Stapert D, Moerman JK, Ford CW: Linezolid, Critical Characteristics. Infection 2000; 28: 60-64.
53. Hanna H, Umphrey J, Tarrand J, Mendoza M, Raad I: Management of an Outbreak of Vancomycin-Resistant Enterococci in the Medical Intensive Care Unit of a Cancer Center. Infect Control Hosp Epidemiol 2001; 22: 217-219.
54. Harbarth S, Sudre P, Dharan S, Cadenas M, Pittet D: Outbreak of Enterobacter cloacae Related to Understaffing, Overcrowding, and Poor Hygiene Practices. Infect Control Hosp Epidemiol 1999; 20: 598-603.
55. Harris J.A.S.: Pediatric Nosocomial Infections: Children are not Little Adults. Infect Control Hosp Epidemiol 1997; 18: 739-742.
56. Hayden MK, Trenholme GM, Schultz JE, Sahm DF: In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate. J Infect Dis 1993; 167: 1224-1227.
57. Hayden MK: Insights into the epidemiology and control of infection with vancomycin-resistant enterococci. Clin Infect Dis 2000; 31: 1058-1065.
58. Henning KJ, Delencastre H, Eagan J, Boone N, Brown A, Chung M, Wollner N, Armstrong D: Vancomycin-Resistant Enterococcus faecium on a Pediatric Oncology Ward: Duration of Stool Shedding and Incidence of Clinical Infection. Pediatr Infect Dis J 1996; 15:848-854.
59. Hopkins HA, Sinkowitz-Cchran RL, Rudin BA, Keyserling HL, Jarvis WR: Vancomycin Use in Pediatric Hematology-Oncology Patients. Infect Control Hosp Epidemiol 2000; 21: 28-50.
60. Hospital Infection Control Practices Advisory Committee (HICPAC): Recommendations for Preventing the Spread of Vancomycin Resistance. Infect Control Hosp Epidemiol 1995; 16: 105-113.
61. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KVI, Shenep JL, Young LS: 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
62. Infektionsschutzgesetz Gesetz zur Verhütung und Bekämpfung von Infektionskrankheiten beim Menschen (Infektionsschutzgesetz - IfSG). Bundesgesetzblatt 2000; Teil 1 Nr.3, Bonn.
63. Jochimsen EM, Fish L, Manning K, Young S, Singer DA, Baker R, Jarvis WR: Control of Vancomycin-Resistant Enterococci at a Community Hospital: Efficacy of Patient and Staff Cohorting. Infect Control Hosp Epidemiol 1999; 20: 106-109.
64. Jones JS, Hoerle D, Riekse R: Stethoscopes: a Potential Vector of Infection? Ann Emerg Med 1995; 26: 296-299.
65. Jones DA, Pulver L, Tai B, Nourse C: Glycopeptide Prescribing in an Australian Tertiary Pediatric Hospital. J Paediatr Child Health 2001; 37: 342-347.
66. Jungbluth GL, Welshman IR, Hopkins NK: Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J 2003; 22 [Suppl 9]: S153-S157.
67. Kahaoglu O, Akpinar M, Nolan B, Inoue S, Zureikat G, Kumar A: Vancomycin Use and Monitoring in Pediatric Patients in a Community Hospital. Infect Control Hosp Epidemiol 1998; 19: 299-301.
68. Kaplan SL, Patterson L, Edwards KM, Azimi PH, Bradley JS, Blumer JL, Tan TQ, Lobeck FG, Anderson DC: Linezolid for the Treatment of Community-Acquired Pneumonia in Hospitalized Children. Linezolid Pediatric Pneumonia Study Group. Pediatr Infect Dis J 2001; 20: 488-494.
69. Kaplan SL, Deville JG, Yogev R, Morfin MR, Wu E, Adler S, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB, Linezolid Pediatric Study Group: Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 2003; 22: 677-686.
70. Kauffman CA: Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. J Antimicrob Chemother 2003; 51 [Suppl 3]: iii 23-30.
71. Kawalec M, Gniadkowski M, Kedzierska J, Skotnicki A, Fiett J, Hryniewicz W: Selection of a teicoplanin-resistant Enterococcus faecium mutant during an outbreak caused by vancomycin-resistant enterococci with the vanB phenotype. J Clin Microbiol 2001; 39: 4274-4282.
72. Kearns GL, Abdel-Rahman S, Blumer JL, Reed MD, James LP, Jacobs RF, Welshman IR, Jungbluth GL, Stalker DJ, Pediatric Pharmacology Research Unit Network: Single Dose Pharmacokinetics of Linezolid in Infants and Children. Pediatr Infect Dis J 2000; 19: 1178-1184.
73. Keyserling HL, Sinkowitz-Cochran RL, Harris JM 2nd, Levine GL, Siegel JD, Stover BH, Lau SA, Jarvis WR, Pediatric Prevention Network: Vancomycin Use in Hospitalized Pediatric patients. Pediatrics 2003; 112e: 104-111.
74. Khare M, Ready D: Antimicrobial therapy of methicillin resistant Staphylococcus aureus infection. Expert Opin Pharmacother 2003; 4: 165-177.
75. Kollef M: Appropriate empirical antibacterial therapy for nosocomial infections: getting it right the first time. Drugs 2003; 63: 2157-2168.
76. Kommission für Krankenhaushygiene und Infektionsprävention am Robert Koch-Institut (RKI) Berlin: Mitteilung zur Händehygiene. Bundesgesundheitsbl Gesundheitsforsch Gesundheitssch 2000; 43: 230-233 [http://www.rki.de/GESUND/HYGIENE/HYGIENE.HTM].
77. Kommission für Krankenhaushygiene und Infektionsprävention am Robert Koch-Institut (RKI), Berlin: Ausbruchsmanagement und strukturiertes Vorgehen bei gehäuftem Auftreten nosokomialer Infektionen. Bundesgesundheitsbl Gesundheitsforsch Gesundheitssch 2002; 45: 180-186 [http://www.rki.de/GESUND/HGIENE/AUSBRUCHSPAPIER.PDF].
78. Kommission für Krankenhaushygiene und Infektionsprävention am Robert Koch-Institut (RKI), Berlin: Anforderungen an die Hygiene bei der Reinigung und Desinfektion von Flächen Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2004; 47: 51-61 [http://www.rki.de/GESUND/ HYGIENE/FLAE-CHE.PDF].
79. Kresken M, Hafner D, Witte W Reinert RR: Resistenzentwicklung bei Staphylokokken und anderen grampositiven Erregern gegenüber Chemotherapeutika im mitteleuropäischen Raum. Chemotherapie Journal 2000; 9 [Suppl 19]: 5-14.
80. Lautenbach E, Schuster MG, Bilker WB, Brennan PJ: The Role of Chloramphenicol in the Treatment of Bloodstream Infection Due to Vancomycin Resistant Enterococcus. Clin Infect Dis 1998; 27: 1259-1265.
81. Le T, Bayer AS: Combination antibiotic therapy for infective endocarditis. Clin Infect Dis 2003; 36: 615-621.
82. Lee E, Burger S, Shah J, Melton C, Mullen M, Warren F, Press R.: Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 2003; 37: 1389-1391.
83. Leavis H, Top J, Shankar N, Borgen K, Bonten M, van Embden J, Willems RJ: A novel putative enterococcal pathogenicity island linked to the esp virulence gene of Enterococcus faecium and associated with epidemicity. J Bacteriol 2004; 186: 672-682.
84. Leclercq R, Derlot E, Duval J, Courvalin P: Plasmid-related Resistance to Vancomycin and Teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319: 157-161.
85. Leber AL, Hindier JF, Kato EO, Bruckner DA, Pegues DA: Laboratory-Based Surveillance for Vancomycin-Resistant Enterococci: Utility of Screening Stool Specimens Submitted for Clostridium difficile Toxin Assay. Infect Control Hosp Epidemiol 2001; 22: 160-164.
86. Lemmen SW, Hafner H, Zolldann D, Stanzel S, Lutticken R.: Distribution of multi-resistant Gram-negative versus Gram-positive bacteria in the hospital inanimate environment. J Hosp Infect 2004; 56: 191-197.
87. Linden PK, Miller CB: Vancomycin-Resistant Enterococci The Clinical Effect of a Common Nosocomial Pathogen. Diagn Microbiol Infect Dis 1999; 33: 113-120.
88. Livermore DM: Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? Antimicrob Chemother 2000; 46: 347-350.
89. Livornese LLJ, Dias S, Samel C: Hospital-Acquired Infection with Vancomycin-Resistant Enterococcus faecium Transmitted by Electronic Thermometers. Ann Intern Med 1992; 117: 112-116.
90. Loeffler AM, Drew RH, Perfect JR, Grethe NI, Stephens JW, Gray SL, Talbot GH: Safety and efficacy of quinupristin/dalfopristin for treatment of invasive Gram-positive infections in pediatric patients. Pediatr Infect Dis J 2002; 21: 950-956.
91. Logsdon BA, Lee KR, Luedtke G, Barrett FF: Evaluation of Vancomycm Use in a Pediatric Teaching Hospital Based on CDC Criteria. Infect Control Hosp Epidemiol 1997; 18: 780-782.
92. Loh W, Ng W, Holton J: Bacterial Flora on the White Coats of Medical Students. J Hosp Infect 2000; 45: 65-68.
93. Losonsky GA, Wolf A, Schwalbe RS, Nataro J, Gibson CB, Lewis EW: Successful treatment of meningitis due to multiply resistant Enterococcus faecium with a combination of intrathecal teicoplanin and intravenous antimicrobial agents. Clin Infect Dis 1994; 19: 163-165.
94. Luginbuhl LM, Rotbart HA, Facklam RR, Roe MH, Elliott JA: Neonatal Enterococcal Sepsis: Case-Control Study and Description of an Outbreak. Pediatr Infekt Dis J 1987; 6: 1022-1030.
95. Lund Soørensen T, Blom M, Monnet DL, Frimodt-Møller N, Lykke Poulson R, Espersen F: Transient Intestinal Carriage after Ingestion of Antibiotic-Resistant Enterococcus faecium from Chicken and Pork. N Engl J Med 2001; 345: 1161-1166.
96. Lyseng-Williamson KA, Goa KL: Linezolid: in infants and children with severe Gram-positive infections. Paediatr Drugs 2003; 5: 419-429.
97. Malik RK, Montecalvo MA, Reale MR, Li K, Maw M, Munoz JL, Gedris C, van Horn K, Carnevale KA, Levi MH, Dweck HS: Epidemiology and Control of Vancomycin-Resistant Enterococci in a Regional Neonatal Intensive Care Unit. Pediatr Infect Dis J 1999; 18: 352-356.
98. Martone WJ: Spread of Vancomycin-Resistant Enterococci: Why Did It Happen in the United States? Infect Control Hosp Epidemiol 1998; 19: 539-545.
99. Masterton R, Drusano G, Paterson DL, Park G: Appropriate antimicrobial treatment in nosocomial infections - the clinical challenges. J Hosp Infect 2003; 55 [Suppl 1]: 1-12.
100. Mathus-Vliegen LM, Binnekade JM, de Haan RJ: Bacterial Contamination of Ready-to-Use 1-L Feeding Bottles and Administration Sets in Severely Compromized Intensive Care Patients. Crit Care Med 2000; 28: 67-73.
101. Matsumura SO, Louie L, Louie M, Simor AE: Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents. Antimicrob Agents Chemother 1999; 43: 2776-2779.
102. McDonald CL, Kuehnert MJ, Tenover FC, Jarvis WR: Vancomycin-Resistant Enterococci Outside the Health-Care Setting: Prevalence, Sources, and Public Health Implications. Emerging Infect Dis 1997; 3: 311-317.
103. McGowan JE, Tenover FC: Control of Antimicrobial Resistance in The Health Care System. Infect Dis Clin North Am 1997; 11: 297-311.
104. McKinnon PS, Davis SL: Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases. Eur J Clin Microbiol Infect Dis 2004; 23: 271-288.
105. McNeeley DF, Saint-Louis F, Noel GJ: Neonatal Enterococcal Bacteriemia: An Increasingly Frequent Event with Potentially Untreatable Pathogens. Pediatr Infect Dis J 1996; 15: 800-805.
106. Meissner HC, Townsend T, Wenman W, Kaplan SL, Morfin MR, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB: Hematologic effects of linezolid in young children. Pediatr Infect Dis J 2003; 22 [9 Suppl]: S186-S192.
107. Moellering RC: Vancomycin-Resistant Enterococci. Clin Infect Dis 1998; 26: 1196-1199.
108. Moellering RC, Linden PK, Reinhardt J, Blumnerg EA, Bompart F, Talbot GH: The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 1999; 44: 251-261.
109. Montecalvo MA, Jarvis WR, Uman J, Shay DK, Petrullo C, Rodney K, Gedris C, Horowitz HW, Wormser GP: Infection-Control Measures Reduce Transmission of Vancomycin-Resistant Enterococci in an Endemic Setting. Ann Intern Med 1999; 131: 269-272.
110. Murray BE: Vancomycin-Resistant Enterococcal Infections. N Engl J Med 2000; 342: 710-721.
111. Muto CA, Jernigan JA, Ostrowsky B E, Richet HM, Jarvis WR, Boyce JM, Farr BM, SHEA: SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003; 24: 362-386.
112. Nachtman A, Verma R, Egnor M: Vancomycin-resistant Enterococcus faecium Shunt Infection in an Infant: An Antibiotic Cure. Microb Drug Resist 1995; 1: 95-95.
113. National Nosocomial Infections Surveillance (NNIS) System Report: Data Summary from January 1999-May 1999, Issued June 1999. Am J Infect Control 1999; 27: 520-532.
114. Neely AN, Maley MP: Survival of enterococci and staphylococci on hospital fabrics and plastic. J Clin Microbiol 2000; 38: 724-726.
115. Noble WC, Virani Z, Cree R: Co-Transfer of Vancomycin and Other Resistance Genes from Enterococcus faecalis NCTC12201 to Staphylococcus aureus. FEMS Micobiol Lett 1992; 72.
116. Noble MA, Isaak-Renton JL, Bryce EA, Roscoe DL, Roberts FJ, Walker M, Scharf S, Walsh A, Altamirano-Dimas M, Gribble M: The Toilet as a Transmission Vector of Vancomycin-Resistant Enterococci. J Hosp Infect 1998; 40: 237-241.
117. Noskin GA, Stosor V, Cooper I, Peterson LR: Recovery of Vancomycin-Resistant Enterococci on Fingertips and Environmental Surfaces. Infect Control Hosp Epidemiol 1995; 16: 577-581.
118. Noskin GA, Bednarz P, Suriano T, Reiner S, Peterson LR: Persistent Contamination of Fabric-Covered Furniture by Vancomycin-Resistant Enterococci: Implications for Upholstery Selection in Hospitals. Am J Infect Control 2000; 28: 311-313.
119. Nourse C, Murphy H, Byrne C, O'meara A, Bretnach F, Kaufmann M, Clarke A, Butler K: Control of a Nosocomial Outbreak of Vancomycin Resistant Enterococcus faecium in a Paediatric Oncology Unit: Risk Factors of Colonisation. Eur J Pediatr 1998; 157: 20-27.
120. Nourse C, Byrne C, Leonard L, Kutler K: Glycopeptide Prescribing in a Tertiary Referal Paediatric Hospital and Applicability of Hospital Infection Control Practises Advisory Committee (HICPAC) Guidelines to Children. Eur J Pediatr 2000; 159: 193-197.
121. Nourse C, Byrne C, Murphy H, Kaufmann ME, Clarke A, Butler K: Eradication of Vancomycin-Resistant Enterococcus faecium From a Paediatric Oncology Unit and Prevalence of Colonization in Hospitalized and Community-Based Children. Epidemiol Infect 2000; 124: 53-59.
122. Nunez S, Moreno A, Green K, Villar J: The Stethoscope in the Emergency Department: a Vector of Infection? Epidemiol Infect 2000; 124: 233-237.
123. O'Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG, Masur H, McCormick RD, Mermel LA, Pearson ML, Raad II, Randolph A, Weinstein RA, Healthcare Infection Control Practices Advisory Committee: Guidelines for the prevention of intravascular catheter-related infections. Infect Control Hosp Epidemiol 2002; 23: 759-769.
124. Orr KE, Gould FK, Perry JD, Ford M, Morgan S, Sisson PR: Therapeutic Beds: the Trojan Horses of the 1990s? Lancet 1994; 344: 65-66.
125. Ostrowsky B, Steinberg JT, Farr B, Sohn AH, Sinkowitz-Cochran RL, Jarvis WR: Reality Check: Should We Try to Detect and Isolate Vancomycin-Resistant Enterococci Patients? Infect Control Hosp Epidemiol 2001; 22: 116-119.
126. Paterson DL: "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004; 38 [Suppl 4]: S341-S345.
127. Pearl TM: The Threat of Vancomycin Resistance. Am J Med 1999; 106 [Suppl 5A]: 26S-37S.
128. Peters G: Multiresistente grampositive Kokken. Dtsch Ärztebl 1998; 95: A1601-1603.
129. Perry C, Marshall R, Jones E: Bacterial contamination of uniforms. J Hosp Infect 2001; 48: 238-241.
130. Perry C., Jarvis B.: Linezolid - A Review of it's Use in the Management of Serious Gram-Positive Infections. Drugs 2001; 61: 525-551.
131. Pittet D, Hugonnet S, Harbarth S, Mourouga P, Sauvan V, Touveneau S, Perneger TV: Effectiveness of a Hospital-Wide Programme to Improve Compliance with Hand Hygiene. Infection Control Programme. Lancet 2000; 356: 1307-1312.
132. Poduval RD, Kamath RP, Corpuz M, Norkus EP, Pitchumoni CS: Clostridium difficile and Vancomycin-Resistant Enterococcus: The New Nosocomial Alliance. Am J Gastroenterol 2000; 95: 3513-3515.
133. Porwancher R, Sheth A, Remphrey S, Taylor E, Hinkle C, Zervos M: Epidemiological Study of Hospital-Acquired Infection with Vancomycin-Resistant Enterococcus faecium: Possible Transmission by an Ear-Probe Thermometer. Infect Control Hosp Epidemiol 1997; 118: 771-774.
134. Puzniak LA, Leet T, Mayfield J, Kollef M, Mundy LM: To gown or not to gown: the effect on acquisition of vancomycin-resistant enterococci. Clin Infect Dis 2002; 35: 18-25.
135. Puzniak LA, Gillespie KN, Leet T, Kollef M, Mundy LM: A cost-benefit analysis of gown use in controlling Vancomycin-resistent Enterococcus transmission: Is it worth the price? Infect Control Hosp Epidemiol 2004; 25: 418-424.
136. Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K: Manipulation of a Hospital Antimicrobial Formulary to Control an Outbreak of Vancomycin-Resistant Enterococci. Clin Infect Dis 1996; 23: 1020-1025.
137. Raad I, Hachem R, Hanna H, Girgawy E, Rolston K, Whimbey E, Husni R, Bodey G: Treatment of Vancomycin-Resistant Enterococcal Infections in the Immunocompromised Host: Quinupristin-Dalfopristin in Combination with Minocycline. Antimicrob Agents Chemother 2001; 45: 3202-3204.
138. Rahal JJ, Urban C, Segal-Maurer S: Nosocomial antibiotic resistance in multiple gram-negative species: experience at one hospital with squeezing the resistance balloon at multiple sites. Clin Infect Dis 2002; 34: 499-503.
139. Reed MD, Blumer JL: Anti-infective Therapy. In Jenson HB, Baltimore RS: Pediatric Infectious Diseases, Principles and Practice. B. Saunders Company 2002, 2nd Edit Chapter 99, 147-190.
140. Rhinehardt E, Smith NE, Wennersten C, Gorss E, Freeman J, Eliopoulos GM, Moellering RC, Goldman DA: Rapid Dissemination of β-Lactamase-Producing Aminoglycoside-Resistant Enterococcus faecalis Among Patients and Staff on an Infant-Toddler Surgical Ward. N Engl J Med 1990; 323: 1814-1818.
141. Rice LB, Hutton-Thomas R, Lakticova V, Helfand MS, Donskey CJ: Beta-lactam antibiotics and gastrointestinal colonization with vancomycin-resistant enterococci. J Infect Dis 2004; 189: 1113-1118.
142. Ridwan B, Mascini E, van Der Reijden N, Verhoei J, Bonten M: What action should be taken to prevent spread of vancomycin resistant enterococci in European hospitals? BMJ 2002; 324: 666-668.
143. Robert Koch-Institut Berlin: Surveillance nosokomialer Infektionen sowie die Erfassung von Erregern mit speziellen Resistenzen und Multiresistenzen. § 6 Abs. 3 und § 23 Abs. 1 und 2 in Verbindung mit § 4 Abs. 2 Nr. 2 IfSG. Rechtliche Voraussetzungen und Umsetzungsempfehlungen. Bundesgesundheitsbl Gesundheits-forsch Gesundheitsschutz 2000; 43: 887-890.
144. Roghman MC, Fink JC, Polish L, Maker T, Brewrink J, Morris JG, Light PD: Colonization with Vancomycin-Resistant Enterococci in Chronic Hemodialysis Patients. Am J Kidney Dis 1998; 32: 254-257.
145. Rubin LG, Tucci V, Cercenado E, Eliopoulos G, Isenberg HD: Vancomycin-Resistant Enterococcus faecium in Hospitalized Children. Infect Control Hosp Epidemiol 1992; 13: 695-699.
146. Rupp ME, Marion N, Fey PD, Bolam DL, Iwen PC, Overfeldt CM, Chapman L: Outbreak of Vancomycin-Resistant Enterococcus faecium in a Neonatal Intensive Care Unit. Infect Control Hosp Epidemiol 2001; 22: 301-303.
147. Rutala WA, Weber DJ, Gergen MF: Studies on the disinfection of VRE-contaminated surfaces. Infect Control Hosp Epidemiol 2000; 21: 548.
148. Rutala WA, Weber DJ: Surface disinfection: should we do it? J Hosp Infect 2001; 48 [Suppl. A]: S64-S68.
149. Saurina G, Landmann D, Quale JM: Activity of Disinfectants Against Vancomycin-Resistant Enterococcus faecium. Infect Control Hosp Epidemiol 1997; 18: 345-347.
150. Schuster F, Graubner UB, Schmid I, Weiss M, Belohradsky BH: Vancomycin-Resistant-Enterococci-Colonisation of 24 Patients in a Pediatric Oncology Unit. Klin Pädiatr 1998; 210: 261-263.
151. Scott G: Prevention and Control of Infections in Intensive Care. Intensive Care Med 2000; 26: S22-S25.
152. Shlaes DM, Gerding DN, John JF, Vraig WA, Bornstein DL, Duncan RA, Eckman MR, Farrer WE, Green WH, Lorian V, Levy S, McGowan JE, Paul SM, Ruskin J, Tenover FC, Watanakunakorn C: Society of Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the Prevention of Resistance in Hospitals. Clin Infect Dis 1997; 25.
153. Simon A, Fleischhack G: Nicht medikamentöse Infektionsprophylaxe in der pädiatrischen Hämatologie/Onkologie. Klin Pädiatr 2001; 213 [Sonderheft 1]: A9-A21.
154. Simon A, Fleischhack G, Marklein G, Ritter J: Chemoprophylaxe bakterieller Infektionskrankheiten in der pädiatrischen Onkologie. Klin Pädiatr 2001; 213 [Sonderheft 1]: A22-A37.
155. Simon A, Schaaf F, Marklein G, Exner M: Methicillin-resistente Staphylococcus aureus (MRSA) - Übersicht zu Bedeutung und Management in der stationären Kinderheilkunde. Hyg Med 2003; 28: 62-74.
156. Simon A, Kasan C: Infektionen in der pädiatrischen Onkologie. Kinder- und Jugendmedizin 2003; 3: 227-239.
157. Simon A: Clostridien-Infektionen. In: Deutsche Gesellschaft für Pädiatrische Infektiologie. Scholz H, Belohradsky BH, Heininger U, Kreth W, Roos R: Handbuch Infektionen bei Kindern und Jugendlichen. 4. Auflage Futuramed-Verlag, München 2003, 250-262.
158. Singh D, Kaur H, Gardner WG, Treen LB: Bacterial contamination of hospital pagers. Infect Control Hosp Epidemiol 2002; 23: 274-276.
159. Singh-Naz N, Sleemi A, Pikis A, Patel KM, Campos JM: Vancomycin-Resistant Enterococcus faecium Colonization in Children. J Clin Microbiol 1999; 37: 413-416.
160. Sinkowitz RL, Keyserling H, Walker TJ, Holland J, Jarvis WR: Epidemiology of Vancomycin Useage at a Children's Hospital, 1993-1995. Pediatric Infect Dis J 1997; 16: 485-489.
161. Slaughter S, Hayden MK, Nathan C, Hu TC, Rice T, Van Voorhis J: A Comparison of the Effect of Universal Use of Gloves and Gowns with that of Glove alone on Acquisition of Vancomycin-Resistant Enterococci in a Medical Intensive Care Unit. Ann Intern Med 1996; 125: 448-456.
162. Spera RV, Farber BF: Multidrug-Resistant Enterococcus faecium: An Untreatable Nosocomial Pathogen. Drugs 1994; 48: 678-688.
163. Stelfox HT, Bates DW, Redelmeier DA: Safety of patients isolated for infection control. JAMA 2003; 290: 1899-1905.
164. Srinivasan A, Song X, Ross T, Merz W, Brower R, Perl TM: A prospective study to determine whether cover gowns in addition to gloves decrease nosocomial transmission of vancomycin-resistant enterococci in an intensive care unit. Infect Control Hosp Epidemiol 2002; 23: 424-428.
165. Stalker DJ, Jungbluth GL: Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42: 1129-1140.
166. Tenorio AR, Badri SM, Sahgal NB, Hota B, Matushek M, Hayden MK, Trenholme GM, Weinstein RA: Effectiveness of Gloves in the Prevention of Hand Carriage of Vancomycin-Resistant Enterococcus Species by Health Care Workers After Patient Care. Clin Infect Dis 2001; 32: 826-829.
167. Tenover FC, Weigel LM, Appelbaum PC, McDougal LK, Chaitram J, McAllister S, Clark N, Killgore G, O'Hara CM, Jevitt L, Patel JB, Bozdogan B: Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother 2004; 48: 275-2780.
168. Toledano H, Schlesinger Y, Raveh D, Rudensky B, Attias D, Eidelman AI, Yinnon AM: Prospective Surveillance of Vancomycin-Resistant Enterococci in a Neonatal Intensive Care Unit. Eur J Clin Microbiol Infect Dis 2000; 19: 282-287.
169. Trautmann M, Ruhnke M, Kresken M, Brauers J, Springsklee M, Marre R : Quinupristin-Dalfopristin (RP 59500, Synercid®) Mikrobiologisches und klinisches Profil der ersten paienteralen Substanzkombination aus der Gruppe der Streptogramine. Chemotherapie Journal 1997; 6: 31-42.
170. Uttley AH, Collins CH, Naedoo J, Heorge RC: Vancomycin-Resistant Enterococci. Lancet I 1988; 57.
171. Van Belkum A, van den Braak N, Thomassen R, Verbrugh H, Endtz H: Vancomycin-Resistant Enterococci in Cats and Dogs. Lancet 1996; 348: 1038-1039.
172. Van der Auwera P, Pensart N, Korten V, Murray BE, Leclercq R: Influence of Oral Glycopeptidees on the Fecal Flora of Healthy Volunteers: Selection of Highly Glycopeptide-Resistant Enterococci. J Infect Dis 1996; 173: 1129-1136.
173. Verma A, Dhawan A, Philpott-Howard J, Rela M, Heaton N, Vergani GM, Wade J: Glycopeptide-resistant Enterococcus faecium infections in paediatric liver transplant recipients: safety and clinical efficacy of quinupristin/ dalfopristin. J Antimicrob Chemother 2001; 47: 105-108.
174. Vidai-Trecan GM, Delamare N, Tcherny-Lessenot S, Lamory J, Baudin F, de Prittwitz M, Salmon-Ceron D: Multidrug-Resistant Bacteria Infection Control: Study of Compliance with Isolation Precautions in a Paris University Hospital. Infect Control Hosp Epidemiol 2001; 22: 109-111.
175. Wade JJ, Desai N, Casewell MW: Hygienic Hand Disinfection for the Removal of Epidemic Vancomycin-Resistant Enterococcus faecium and Gentamicin-Resistant Enterobacter cloacae. J Hosp Infect 1991; 18: 211-218.
176. Weber DJ, Rutala WA: Role of Environmental Contamination in the Transmission of Vancomycin-Resistant Enterococci. Infect Control Hosp Epidemiol 1997; 18: 306-309.
177. Weinstein MR, Dedier H, Brunton J, Campbell I, Conly JM: Lack of Efficacy of Oral Bacitracin plus Doxycycline for the Eradication of Stool Colonization with Vancomycin-Resistant Enterococcus faecium. Clin Infect Dis 1999; 29: 361-366.
178. Weinstein RA: Controlling Antimicrobial Resistance in Hospitals; Infection Control and Use of Antibiotics. Emerg Infect Dis 2001; 7: 188-192.
179. Wendt C, Weisenthal B, Dietz E, Rüden H: Survival of Vancomycin-Resistant and Vancomycin-Susceptible Enterococci on Dry Surfaces. J Clin Microbiol 1998; 36: 3734-3736.
180. Wendt C, Rüden H, Edmond M: Vancomycin-resistente Enterokokken - Epidemiologie, Risikofaktoren und Prävention. Dtsch Ärztebl 1998; 95: A1604-1611.
181. Werner G, Klare I, Spencker FB, Witte W: Intra-hospital dissemination of quinupristin/dalfopristin- and vancomycin-resistant Enterococcus faecium in a paediatric ward of a German hospital. J Antimicrob Chemother 2003; 52: 113-115.
182. Whitener CJ, Park SY, Browne FA, Parent LJ, Julian K, Bozdogan B, Appelbaum PC, Chaitram J, Weigel LM, Jernigan J, McDougal LK, Tenover FC, Fridkin SK: Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure. Clin Infect Dis 2004; 38: 1049-1055.
183. Wilcox JH, Jones BL: Enterococci and Hospital Laundry. Lancet 1995; 345: 594.
184. Wilkins MC: Residual Bacterial Contamination on Reusable Pulse Oximetry Sensors. Respir Care 1993; 38: 1155-1160.
185. Willems RJ, Homan W, Top J, van Santen-Verheuvel M, Tribe D, Manzioros X, Gaillard C, Vandenbroucke-Grauls CM, Mascini EM, van Kregten E, van Embden JD, Bonten MJ: Variant esp gene as a marker of a distinct genetic lineage of vancomycin-resistant Enterococcus faecium spreading in hospitals. Lancet 2001; 357: 853-855.
186. Wong MT, Kauffman CA, Standiford HC, Linden P, Fort G, Fuchs HJ, Porter SB, Wenzel RP, Ramoplanin VRE2 Clinival Stury Group: Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin Infect Dis 2001; 33: 1476-1482.
187. Wright MO, Hebden JN, Harris AD, Shanholtz CB, Standiford HC, Furuno JP, Perencevich EN: Aggressive control measures for resistant Acinetobacter baumannii and the impact on acquisition of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in a medical intensive care unit. Infect Control Hosp Epidemiol 2004; 25: 167-168.
188. Zachary KC, Bayne PS, Morrison VJ, Ford DS, Silver LC, Hooper DC: Contamination of gowns, gloves, and stethoscopes with vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 2001; 22: 560-564.
189. Zeana C, Kubin CJ, Delia-Latta P, Hammer SM: Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clin Infect Dis 2001; 33: 477-482.